BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: BRCA2 mutation has a more substantial impact on the homologous recombination and superior therapeutic response to platinum-based chemotherapy than BRCA1 mutation. Whether BRCA2-mutated patients could benefit more from PARPi than BRCA1-mutated patients remains unclear. We performed a meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shan, Tao, Li, Dai, Haiyun, Gong, Xue, Zhuo, Yuguo, Xiang, Hui, Zhao, Yueyang, Gao, Qing, Deng, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580941/
https://www.ncbi.nlm.nih.gov/pubmed/34778033
http://dx.doi.org/10.3389/fonc.2021.718871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580941/
https://www.ncbi.nlm.nih.gov/pubmed/34778033
http://dx.doi.org/10.3389/fonc.2021.718871

Ejemplares similares